IGF-1 LR3 vs Follistatin 344
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), giving it a longer half-life and higher receptor availability than native IGF-1. Preclinical research has examined its effects on PI3K/Akt/mTOR signaling, muscle protein synthesis, and cellular proliferation models. Follistatin 344 is the 344-amino-acid isoform of follistatin, a glycoprotein that binds and neutralizes members of the TGF-beta superfamily — most notably myostatin and activin. By antagonizing myostatin (a negative regulator of muscle growth), Follistatin 344 has been studied in muscle hypertrophy and tissue regeneration models. It works upstream of the growth pathway rather than directly stimulating receptors.
IGF-1 LR3
Follistatin 344
The Verdict
IGF-1 LR3 and Follistatin 344 both appear in muscle and growth research but operate through opposite directions in the signaling pathway. IGF-1 LR3 directly activates growth signaling at the receptor level, while Follistatin 344 removes a negative regulator (myostatin) to allow endogenous growth signaling to proceed. They are mechanistically complementary — some research protocols use both to study upstream and downstream effects on the same biological outcome.
Explore These Products
IGF-1 LR3
A modified form of insulin-like growth factor-1 with an extended half-life, studied for its potent effects on cell proliferation, tissue growth, and metabolic regulation.
View Details →Follistatin 344
A naturally occurring glycoprotein that binds and neutralizes myostatin, activin, and other TGF-beta superfamily members, studied for its role in muscle growth and tissue regeneration.
View Details →IGF-1 LR3 vs Follistatin 344 — FAQ
Why is IGF-1 LR3 modified instead of using native IGF-1?
How does Follistatin work without binding to a receptor?
Can they be combined?
What is the regulatory status?
References
Primary sources for key clinical and regulatory claims on this page.
- IGF-I receptor signalling and the regulation of skeletal muscle mass — PubMed / Int J Biochem Cell Biol . Comprehensive review of IGF-1 receptor signaling and the PI3K/Akt/mTOR pathway in muscle research.
- Follistatin antagonizes activin signaling and acts with notch to regulate muscle growth — PubMed / Mol Cell Biol . Primary preclinical reference for follistatin antagonism of TGF-beta family signaling in muscle models.
Keep Researching
Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.